Literature DB >> 11433229

Advanced glycosylation end products stimulate collagen mRNA synthesis in mesangial cells mediated by protein kinase C and transforming growth factor-beta.

Y S Kim1, B C Kim, C Y Song, H K Hong, K C Moon, H S Lee.   

Abstract

Advanced glycosylation end products (AGE) seem to be implicated in the pathogenesis of diabetic nephropathy. The present study has examined the effects of AGE on protein kinase C (PKC) activity and transforming growth factor-beta1 (TGF-beta1) in relation to collagen gene regulation in cultured human mesangial cells (HMCs). Quiescent HMCs were exposed to serum-free media containing bovine serum albumin (BSA), AGE-modified BSA (AGE-BSA), or glycated BSA in which AGE formation was prevented by the use of aminoguanidine (BSA-AM). AGE-BSA (200 microg/mL) induced a peak membrane-associated PKC activity, particularly PKC-a, at 4 hours. AGE-BSA stimulated alpha1(I) and alpha1(IV) collagen mRNA expression after 24-hour incubation with HMCs, which remained elevated until hour 60. HMCs incubated with AGE-BSA induced a significant inhibition of cell proliferation compared with cells incubated with BSA. AGE-BSA stimulated TGF-beta mRNA and protein expression in HMCs. The TGF-beta secreted by HMCs was shown by CCL-64 mink lung cell assay to be bioactive. In contrast, BSA-AM did not affect either collagen or TGF-beta mRNA or protein expression in HMCs. The stimulatory effects of AGE-BSA on collagen gene regulation in HMCs could be negated by the pretreatment of HMCs with GF 109203X for 30 minutes or with phorbol myristate acetate for 24 hours before AGE-BSA administration. Neutralizing antibody to TGF-beta inhibited increased collagen mRNA expression by HMCs exposed to AGE-BSA. These results suggest that AGE-BSA stimulates collagen mRNA expression by activating PKC and the transcriptional upregulation of TGF-beta1 in HMCs. Thus, PKC and TGF-beta may function as key signaling intermediaries in the AGE-up-regulated collagen gene expression pathway in HMCs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11433229     DOI: 10.1067/mlc.2001.115494

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  10 in total

Review 1.  Mechanisms and interventions in peritoneal fibrosis.

Authors:  Yasuhiko Tomino
Journal:  Clin Exp Nephrol       Date:  2011-09-21       Impact factor: 2.801

Review 2.  Encapsulating peritoneal sclerosis: the state of affairs.

Authors:  Mario R Korte; Denise E Sampimon; Michiel G H Betjes; Raymond T Krediet
Journal:  Nat Rev Nephrol       Date:  2011-08-02       Impact factor: 28.314

3.  Renal clearance of glycolaldehyde- and methylglyoxal-modified proteins in mice is mediated by mesangial cells through a class A scavenger receptor (SR-A).

Authors:  K Nakajou; S Horiuchi; M Sakai; N Haraguchi; M Tanaka; M Takeya; M Otagiri
Journal:  Diabetologia       Date:  2005-01-15       Impact factor: 10.122

Review 4.  Fibrosis of Peritoneal Membrane as Target of New Therapies in Peritoneal Dialysis.

Authors:  Valentina Masola; Mario Bonomini; Silvio Borrelli; Lorenzo Di Liberato; Luigi Vecchi; Maurizio Onisto; Giovanni Gambaro; Roberto Palumbo; Arduino Arduini
Journal:  Int J Mol Sci       Date:  2022-04-27       Impact factor: 6.208

5.  Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor beta-independent pathway.

Authors:  Guihua Zhou; Cai Li; Lu Cai
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

6.  Transforming growth factor-beta induces cellular injury in experimental diabetic neuropathy.

Authors:  Muragundla Anjaneyulu; Alison Berent-Spillson; Tatsuya Inoue; Joungil Choi; Kay Cherian; James W Russell
Journal:  Exp Neurol       Date:  2008-03-02       Impact factor: 5.330

Review 7.  Protective measures against ultrafiltration failure in peritoneal dialysis patients.

Authors:  Anna Rita Aguirre; Hugo Abensur
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

Review 8.  Advanced glycation end products and diabetic complications.

Authors:  Varun Parkash Singh; Anjana Bali; Nirmal Singh; Amteshwar Singh Jaggi
Journal:  Korean J Physiol Pharmacol       Date:  2014-02-13       Impact factor: 2.016

9.  Erk5 is a mediator to TGFβ1-induced loss of phenotype and function in human podocytes.

Authors:  Irbaz I Badshah; Deborah L Baines; Mark E Dockrell
Journal:  Front Pharmacol       Date:  2014-04-21       Impact factor: 5.810

10.  Pathway-Based Genome-Wide Association Studies for Plasma Triglycerides in Obese Females and Normal-Weight Controls.

Authors:  Hongxiao Jiao; Kai Wang; Fuhua Yang; Struan F A Grant; Hakon Hakonarson; R Arlen Price; Wei-Dong Li
Journal:  PLoS One       Date:  2015-08-26       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.